The FDA Recalled These Popular Neutrogena Makeup Wipes Due to a Bacteria Risk

Neutrogena has initiated a voluntary Class II recall of its Makeup Remover Ultra-Soft Cleansing Towelettes after the FDA identified *Pluralibacter gergoviae* bacterium, which poses a mid-level health risk, particularly to immunocompromised individuals. This recall, affecting lot code 1835U6325A, involves 1,312 cases distributed across Florida, Georgia, South Carolina, and Texas, indicating potential brand reputation and sales impacts for the company.

Analysis

Neutrogena, a subsidiary of Johnson & Johnson (JNJ), has initiated a voluntary Class II recall of its Makeup Remover Ultra-Soft Cleansing Towelettes due to the presence of *Pluralibacter gergoviae*. This bacterium, identified by the FDA, poses a mid-level health threat, primarily to immunocompromised individuals, with a remote probability of serious adverse health consequences for healthy persons. The recall specifically targets lot code 1835U6325A, affecting 1,312 cases distributed across Florida, Georgia, South Carolina, and Texas.

While classified as a Class II recall, indicating temporary or medically reversible adverse health consequences, the incident carries reputational risks for the Neutrogena brand and its parent company, JNJ. The presence of *Pluralibacter gergoviae* has been linked to severe infections, including UTIs and sepsis, and a similar issue led to a Jergen's recall in 2022, highlighting a recurring industry challenge in beauty product safety. The moderately negative sentiment (-0.5) and cautious tone reflect these concerns.

Despite the negative sentiment, the market impact score is low at 0.15, suggesting that investors currently perceive this as a contained issue with limited financial ramifications for JNJ. The recall's limited geographic scope and specific lot code, alongside the voluntary nature, may mitigate broader financial penalties or widespread sales disruption. However, ongoing regulatory scrutiny and consumer confidence remain key variables.

Key Decisions for Investors

• Monitor JNJ's official response and any further FDA actions regarding product safety standards and quality control processes.
• Assess the potential for broader brand damage to Neutrogena and its impact on JNJ's consumer health segment, particularly if the issue escalates beyond the current Class II classification.
• Consider the implications for other beauty and personal care companies regarding quality control and bacterial contamination risks, especially given the prior Jergen's incident involving the same bacterium.